Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of sulfanilides, specifically a benzoic acid derivative substituted with an ethyl group at position 3, a methyl group at position 2, and a [(4-fluorophenyl)sulfonyl]amino group at position 6. It has been cataloged as DrugBank ID DB07746 and ChemSpider ID 22377130. The molecular formula is C16H16FNO4S with an average mass of approximately 337.37 g/mol[1][2][10]. There are no approved medical indications or clinical trials reported for this compound; it is considered experimental and preclinical[1][4]. No detailed mechanism of action or biological target has been established in public sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-ethyl-6-{[(4-fluorophenyl)sulfonyl]amino}-2-methylbenzoic acid.